RA0108

antibody from Oursmab
Targeting: CD4
Provider product page for RA0108
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0108 - Provider product page
Provider
Oursmab
Product name
Ibalizumab (Biosimilar Reference Antibody) (CD4)
Antibody type
Monoclonal
Description
Ibalizumab is a humanized monoclonal IgG4 antibody approved for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced adults. It represents a first-in-class post-attachment HIV-1 inhibitor. Unlike most antiretrovirals that target viral enzymes (reverse transcriptase, integrase, protease) or the CCR5 co-receptor, ibalizumab has a unique host-directed mechanism. It binds to domain 2 of the CD4 receptor on the surface of host T cells. This binding does not block HIV-1's initial attachment to CD4 but induces conformational changes that prevent the essential post-attachment steps required for viral entry, specifically the fusion of the viral and host cell membranes. It is administered intravenously every two weeks.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
CD4 protein structure - RA0108 shown in red.